Literature DB >> 23973912

Nanopreparations to overcome multidrug resistance in cancer.

Niravkumar R Patel1, Bhushan S Pattni, Abraham H Abouzeid, Vladimir P Torchilin.   

Abstract

Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance. A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties. In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing microtumor tissues in vitro are discussed in detail.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Combination therapy; Multidrug resistance; Nanopreparations; Spheroid culture

Mesh:

Substances:

Year:  2013        PMID: 23973912      PMCID: PMC3840079          DOI: 10.1016/j.addr.2013.08.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  240 in total

1.  Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.

Authors:  Daniel S Metzinger; Douglas D Taylor; Cicek Gercel-Taylor
Journal:  Cancer Lett       Date:  2005-06-29       Impact factor: 8.679

Review 2.  Hypoxia and anemia: effects on tumor biology and treatment resistance.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Transfus Clin Biol       Date:  2005-02       Impact factor: 1.406

3.  Tumour cell proliferation in relation to the vasculature.

Authors:  D G Hirst; J Denekamp
Journal:  Cell Tissue Kinet       Date:  1979-01

Review 4.  Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.

Authors:  Meysam Abbasi; Afsaneh Lavasanifar; Hasan Uludag
Journal:  Med Res Rev       Date:  2011-04-26       Impact factor: 12.944

Review 5.  Tumor pH and its measurement.

Authors:  Xiaomeng Zhang; Yuxiang Lin; Robert J Gillies
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

6.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

7.  Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger.

Authors:  Jun-Jie Yin; Fang Lao; Jie Meng; Peter P Fu; Yuliang Zhao; Gengmei Xing; Xueyun Gao; Baoyun Sun; Paul C Wang; Chunying Chen; Xing-Jie Liang
Journal:  Mol Pharmacol       Date:  2008-07-17       Impact factor: 4.436

8.  Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.

Authors:  A Tröger; M Siepermann; C Mahotka; N Wethkamp; H Bülle; H-J Laws; G Escherich; G Janka-Schaub; U Göbel; D Dilloo
Journal:  Klin Padiatr       Date:  2007 May-Jun       Impact factor: 1.349

9.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

Review 10.  The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).

Authors:  L J A Hardwick; S Velamakanni; H W van Veen
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

View more
  65 in total

Review 1.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.

Authors:  Bhushan S Pattni; Srikar G Nagelli; Bhawani Aryasomayajula; Pranali P Deshpande; Abhijit Kulkarni; William C Hartner; Ganesh Thakur; Alexei Degterev; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 4.  Engineering exosomes: a new direction for anticancer treatment.

Authors:  Benshuai You; Wenrong Xu; Bin Zhang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 5.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 6.  Photodynamic therapy: one step ahead with self-assembled nanoparticles.

Authors:  Pinar Avci; S Sibel Erdem; Michael R Hamblin
Journal:  J Biomed Nanotechnol       Date:  2014-09       Impact factor: 4.099

7.  Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines.

Authors:  Rositsa Mihaylova; Anife Ahmedova; Denitsa Momekova; Georgi Momekov; Nikolay Danchev
Journal:  Invest New Drugs       Date:  2019-02-08       Impact factor: 3.850

8.  Combination Nanopreparations of a Novel Proapoptotic Drug - NCL-240, TRAIL and siRNA.

Authors:  Robert Riehle; Bhushan Pattni; Aditi Jhaveri; Abhijit Kulkarni; Ganesh Thakur; Alexei Degterev; Vladimir Torchilin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

Review 9.  Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.

Authors:  Mostafa Akbarzadeh Khiavi; Azam Safary; Jaleh Barar; Amir Ajoolabady; Mohammad Hossein Somi; Yadollah Omidi
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

10.  Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.

Authors:  Chunbai He; Demin Liu; Wenbin Lin
Journal:  Biomaterials       Date:  2014-10-12       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.